Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The Heart Failure Revascularisation Trial (HEART)

Cleland, John G.F., Calvert, Melanie, Freemantle, Nick, Arrow, Yvonne, Ball, Stephen G., Bonser, Robert S., Chattopadhyay, Sudipta, Norell, Michael S., Pennell, Dudley J., Senior, Roxy·2011·European Journal of Heart Failure

Abstract

Aims: Revascularization is frequently advocated to improve ventricular function and prognosis for patients with heart failure due to coronary artery disease, especially when there is evidence of extensive myocardial viability. Methods and results: Patients with heart failure, coronary artery disease, and a left ventricular (LV) ejection fraction <35%, who had a substantial volume of viable myocardium with contractile dysfunction assessed by any standard imaging technique, were randomly assigned to a strategy of conservative management vs. angiography with the intent of percutaneous or surgical revascularization. Patients requiring revascularization for angina or too frail for surgery were excluded. Only 138 of the planned 800 patients were enrolled because of withdrawal of funding due to slow recruitment. Also, a larger trial (The Surgical Treatment for Ischemic Heart Failure Trial) addressing a similar question became available, which investigators were encouraged to join. Of 69 patients assigned to the invasive strategy, 6 refused angiography, 2 died as a result of the diagnostic procedure, 14 were considered unsuitable for revascularization, 2 refused surgery, and 45 had revascularization. After a median follow-up of 59 (inter-quartile range: 33–63) months, there were 51 (37%) deaths; 25 (37%) in those assigned to the conservative strategy, and 26 (38%) in those assigned to the invasive strategy, 13 (29%) of whom had been revascularized. Conclusion: A conservative management strategy may not be inferior to one of coronary arteriography with the intent to revascularize in patients with heart failure, LV systolic dysfunction, and extensive myocardial viability. However, this study was underpowered and, further, larger trials are required to settle this issue. Clinical trials Registration No: ISRCTN86284615

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hfq230

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 233

Metadata

Authors
Cleland, J. G. F., Calvert, M., Freemantle, N., Arrow, Y., Ball, S. G., Bonser, R. S., Chattopadhyay, S., Norell, M. S., Pennell, D. J., & Senior, R.
Venue
European Journal of Heart Failure
Published
2011-02-01
Volume
13
Issue
2
Pages
227-233
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W1969573398
Cited by
233
References
1
FWCI
10.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Heart Failure Revascularisation Trial (HEART). https://app.cochat.ai/papers/10.1093/eurjhf/hfq230
The paper
Cleland, J. G. F., Calvert, M., Freemantle, N., Arrow, Y., Ball, S. G., Bonser, R. S., Chattopadhyay, S., Norell, M. S., Pennell, D. J., & Senior, R. (2011). The Heart Failure Revascularisation Trial (HEART). European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfq230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.